| Compounds | Topics | Title | Date |
|---|---|---|---|
| CBD,THC | addiction,anti-psychotic via review | The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. | Jul 2019 |
| CBD and THC mixtures showed positive effects in reducing short-term withdrawal and craving in cannabis use disorders. Studies on schizophrenia and comorbid substance use are lacking. Future studies should focus on the effects of CBD on psychotic disorders in different stages of illness, together with the effects on comorbid substance use. | |||
| CBD | anti-psychotic via review | Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. | Apr 2006 |
| The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD | |||
| CBD | anti-psychotic via review | Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. | Mar 2010 |
| In this review, both preclinical and clinical studies investigating the potential antipsychotic effects of both CBD and SR141716 are presented together with the possible underlying mechanisms of action. | |||
| THCV | anti-psychotic,schitzophrenia in vitro via experiment | The phytocannabinoid, ??-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effects. | Mar 2015 |
|
Action Pathway: 5-HT1A Our findings suggest that THCV can enhance 5-HT1A receptor activation, and that some of its apparent antipsychotic effects may depend on this enhancement. We conclude that THCV has therapeutic potential for ameliorating some of the negative, cognitive and positive symptoms of schizophrenia. | |||